Morgan Stanley Maintains Overweight on Revolution Medicines, Lowers Price Target to $247

Benzinga · 15h ago
Morgan Stanley analyst Sean Laaman maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target from $272 to $247.